Vitalibis, Inc. (VCBDQ) — AI-Aktienanalyse

Vitalibis, Inc. is a technology-based formulator of phytocannabinoid-rich hemp products, personal care items, and nutritional products. The company markets consumer products under its Vitalibis brand and also sells water-soluble phytocannabinoid-rich hemp powder.

Unternehmensueberblick

Kurzfassung:

Vitalibis, Inc. formulates and markets phytocannabinoid-rich hemp products, personal care items, and nutritional products under the Vitalibis brand. Operating in the specialty and generic drug manufacturing sector, the company focuses on technology-based formulations and direct-to-consumer sales, including water-soluble hemp powder, differentiating itself through brand-building and specialized product offerings.

Ueber VCBDQ

Vitalibis, Inc., founded in 2014 and headquartered in Las Vegas, Nevada, operates as a technology-based formulator of phytocannabinoid-rich hemp products containing cannabidiol (CBD). The company develops, markets, and sells a range of consumer products under the Vitalibis brand, focusing on personal care and nutritional supplements. In addition to finished goods, Vitalibis also offers water-soluble phytocannabinoid-rich hemp powder, catering to both individual consumers and potential business partners. Originally named Sheng Ying Entertainment Corp., the company rebranded as Vitalibis, Inc. in February 2018, signaling a strategic shift towards the burgeoning hemp and CBD market. Vitalibis aims to capitalize on the growing demand for hemp-derived products by offering innovative formulations and a direct-to-consumer sales model. The company's focus on technology-driven product development and brand-building positions it within the competitive landscape of the specialty and generic drug manufacturing industry, specifically targeting the niche market of CBD and hemp-based wellness products.

Investmentthese

Vitalibis, Inc. presents a speculative investment opportunity within the high-growth CBD and hemp market. The company's focus on technology-based formulations and direct-to-consumer sales could drive revenue growth, although profitability remains a challenge, as evidenced by a negative profit margin of -2257.9%. Key value drivers include successful product innovation, effective marketing strategies to build brand awareness, and expansion into new distribution channels. The company's gross margin of 46.4% indicates potential for profitability if operating expenses are managed effectively. However, investors should be aware of the risks associated with OTC-listed companies, including limited liquidity and disclosure requirements. The company's beta of -0.46 suggests a low correlation with the overall market, which may offer some downside protection during market downturns.

Branchenkontext

Vitalibis, Inc. operates within the rapidly evolving market for CBD and hemp-derived products. This sector has experienced substantial growth in recent years, driven by increasing consumer awareness of the potential health benefits of CBD and changing regulatory landscapes. However, the industry is also characterized by intense competition, with numerous companies vying for market share. Vitalibis competes with both established players in the pharmaceutical and wellness industries and smaller, niche brands. The regulatory environment remains uncertain, with ongoing debates about the legality and safety of CBD products, which could impact the company's future growth prospects.

Drug Manufacturers - Specialty & Generic

Healthcare

Wachstumschancen

Expansion of Product Line: Vitalibis can expand its product line to include a wider range of CBD-infused products, such as edibles, topicals, and beverages. The global CBD market is projected to reach $55.79 billion by 2028, presenting a significant opportunity for Vitalibis to capture a larger share of the market. Successful product innovation and diversification could drive revenue growth and increase brand recognition.
Strategic Partnerships: Forming strategic partnerships with established retailers, distributors, or healthcare providers could significantly expand Vitalibis's reach and market penetration. Collaborations with wellness centers, spas, or fitness studios could provide access to new customer segments and enhance brand credibility. These partnerships could be established within the next 1-2 years, providing a near-term growth catalyst.
International Expansion: Expanding into international markets, particularly in Europe and Asia, could unlock significant growth potential for Vitalibis. These regions are experiencing increasing demand for CBD products, driven by changing consumer preferences and evolving regulatory frameworks. Successful international expansion would require careful market research, regulatory compliance, and adaptation of product offerings to local preferences. This expansion could be pursued over the next 3-5 years.
Development of Proprietary Formulations: Investing in research and development to create proprietary CBD formulations with enhanced efficacy and bioavailability could provide a significant competitive advantage for Vitalibis. Developing patented or patent-pending formulations would differentiate the company's products from competitors and create barriers to entry. This could involve collaborations with research institutions or universities and could yield results within the next 2-3 years.
Direct-to-Consumer (DTC) Optimization: Enhancing the company's direct-to-consumer sales channel through improved website design, targeted marketing campaigns, and personalized customer experiences could drive revenue growth and improve customer loyalty. Investing in data analytics and customer relationship management (CRM) systems could enable Vitalibis to better understand customer preferences and tailor its offerings accordingly. These improvements could be implemented within the next 6-12 months, providing a short-term boost to sales.

Vitalibis operates as a technology-based formulator of phytocannabinoid-rich hemp products.
The company's gross margin stands at 46.4%, indicating potential for profitability with effective cost management.
Vitalibis markets and sells consumer products under the Vitalibis brand, focusing on direct-to-consumer sales.
The company's profit margin is -2257.9%, reflecting significant losses.
Vitalibis's beta is -0.46, suggesting a low correlation with the overall market.

Was das Unternehmen tut

Formulates phytocannabinoid-rich hemp products.
Develops personal care products.
Creates nutritional products.
Markets and sells consumer products under the Vitalibis brand.
Sells water-soluble phytocannabinoid-rich hemp powder.
Focuses on technology-based product development.

Geschaeftsmodell

Develops and formulates CBD-infused products.
Markets products directly to consumers through its Vitalibis brand.
Sells water-soluble hemp powder to businesses and consumers.

Individual consumers seeking CBD-based wellness products.
Customers interested in personal care and nutritional supplements.
Businesses that utilize water-soluble hemp powder in their products.

Brand recognition through the Vitalibis brand.
Technology-based formulation expertise.
Direct-to-consumer sales channel.

Katalysatoren

Upcoming: Potential regulatory changes in the CBD market could create new opportunities or challenges for Vitalibis.
Ongoing: Increasing consumer awareness of CBD and hemp-derived products could drive demand for Vitalibis's products.
Upcoming: Launch of new CBD-infused products could boost revenue and market share within the next year.
Ongoing: Expansion of the direct-to-consumer sales channel could improve customer acquisition and retention.

Risiken

Potential: Intense competition in the CBD market could erode Vitalibis's market share and profitability.
Potential: Changing regulatory landscape for CBD products could negatively impact Vitalibis's operations.
Ongoing: Negative profit margin (-2257.9%) raises concerns about the company's financial sustainability.
Potential: Limited liquidity due to OTC listing could make it difficult to buy or sell shares.
Ongoing: Dependence on a single brand (Vitalibis) could make the company vulnerable to negative publicity or changing consumer preferences.

Staerken

Technology-based formulation capabilities.
Established brand name (Vitalibis).
Direct-to-consumer sales channel.
Offers water-soluble hemp powder.

Schwaechen

Negative profit margin (-2257.9%).
Limited financial resources.
OTC listing with lower liquidity.
Small market capitalization.

Chancen

Expansion of product line.
Strategic partnerships with retailers and distributors.
International market expansion.
Development of proprietary formulations.

Risiken

Intense competition in the CBD market.
Changing regulatory landscape for CBD products.
Fluctuations in raw material prices.
Potential for negative publicity or consumer backlash.

Wettbewerber & Vergleichsunternehmen

Cannabis Strategic Ventures Inc — Focuses on cannabis cultivation and retail. — (CSTF)
Endonine Canada Inc — Specializes in cannabis extraction and processing. — (EDNEF)
Hope Hemp Inc — Cultivates and distributes hemp products. — (HOPHF)
HURCULES INC. — Operates in the cannabis and hemp industry with a focus on cultivation and distribution. — (HURA)
KORB BIOPHARMA CORP — Focuses on developing cannabinoid-based pharmaceuticals. — (KRBP)

Key Metrics

Volume: 0
MoonshotScore: 61/100

Company Profile

CEO: Steven P. Raack
Headquarters: Las Vegas, US
Founded: 2018

AI Insight

AI analysis pending for VCBDQ

OTC Tier: OTC Other
Disclosure Status: Unknown

Fragen & Antworten

What does Vitalibis, Inc. do?

Vitalibis, Inc. operates as a technology-based formulator, developer, and marketer of phytocannabinoid-rich hemp products, personal care items, and nutritional products. The company focuses on leveraging the growing market for CBD-infused products by offering a range of consumer goods under its Vitalibis brand. In addition to finished products, Vitalibis also sells water-soluble phytocannabinoid-rich hemp powder, catering to both individual consumers and potential business partners. The company's business model centers around direct-to-consumer sales and brand-building within the competitive CBD and wellness market.

What do analysts say about VCBDQ stock?

As of 2026-03-16, formal analyst coverage of Vitalibis, Inc. (VCBDQ) is limited, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as the P/E ratio (-0.00), reflect the company's current lack of profitability. Growth considerations revolve around the company's ability to expand its product line, increase brand awareness, and navigate the evolving regulatory landscape for CBD products. Investors should conduct their own thorough research and consider the risks associated with OTC-listed stocks before making any investment decisions.

What are the main risks for VCBDQ?

The main risks for Vitalibis, Inc. include intense competition in the rapidly growing CBD market, which could pressure pricing and erode market share. The evolving regulatory landscape for CBD products poses another significant risk, as changes in regulations could impact the legality and marketability of the company's products. The company's negative profit margin (-2257.9%) raises concerns about its financial sustainability and ability to generate positive cash flow. As an OTC-listed stock, VCBDQ also faces risks related to limited liquidity and disclosure requirements.

Is VCBDQ a good investment right now?

Use the AI score and analyst targets on this page to evaluate Vitalibis, Inc. (VCBDQ). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for VCBDQ?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates Vitalibis, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find VCBDQ financial statements?

Vitalibis, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.

What do analysts say about VCBDQ?

Analyst consensus targets and ratings for Vitalibis, Inc. are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.

How volatile is VCBDQ stock?

Check the beta and historical price range on this page to assess Vitalibis, Inc.'s volatility relative to the broader market.